In this issue:
Rituximab for pemphigus vulgaris
Short-term relapse after rituximab for pemphigus vulgaris
Ixekizumab safety in psoriasis,
PsA and axial spondyloarthritis
Ixekizumab vs ustekinumab for nail psoriasis
Melanoma risk with biologic therapy for inflammatory diseases
Risk of IBD development during inhibition of IL-17
Dupilumab for pruritis in moderate-to-severe atopic dermatitis
Dupilumab effects on SCORAD outcomes in moderate-to-severe atopic dermatitis
Adalimumab for hidradenitis suppurativa
Please login below to download this issue (PDF)